Perceptive Advisors’s Adaptive Biotechnologies ADPT Stock Holding History

Perceptive Advisors’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$26.1M	Buy	1,217,325 +1,064,825	+698%	+$16.3M	0.39%	51
2026 Q1	$2.12M	Buy	+152,500	New	+$2.43M	0.04%	84
2025 Q2	–	Sell	-930,972	Closed	-$6.92M	–	87
2025 Q1	$6.92M	Buy	+930,972	New	+$7.16M	0.24%	62
2022 Q1	–	Sell	-352,804	Closed	-$9.9M	–	136
2021 Q4	$9.9M	Hold	352,804	–	–	0.15%	94
2021 Q3	$12M	Hold	352,804	–	–	0.17%	93
2021 Q2	$14.4M	Hold	352,804	–	–	0.19%	99
2021 Q1	$14.2M	Sell	352,804 -552,050	-61%	-$29.9M	0.18%	93
2020 Q4	$53.5M	Buy	904,854 +74,854	+9%	+$3.86M	0.57%	44
2020 Q3	$40.4M	Buy	830,000 +350,000	+73%	+$14.7M	0.59%	45
2020 Q2	$23.2M	Sell	480,000 -15,000	-3%	-$547K	0.38%	56
2020 Q1	$13.4M	Buy	495,000 +190,000	+62%	+$5.3M	0.35%	53
2019 Q4	$9.13M	Buy	305,000 +10,000	+3%	+$287K	0.18%	68
2019 Q3	$9.12M	Buy	295,000 +10,000	+4%	+$408K	0.25%	58
2019 Q2	$13.8M	Buy	+285,000	New	+$12.6M	0.32%	56

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Perceptive Advisors's ADPT Position: Q2 2026 in Review

Perceptive Advisors increased its Adaptive Biotechnologies (ADPT) stake by 698% in Q2 2026, buying an estimated $16.3M and bringing the position to 1,217,325 shares worth $26.1M. The position accounts for 0.39% of the portfolio, ranked #51.

Perceptive Advisors first reported a position in ADPT in Q2 2019 and has held it in 14 quarters since. The position peaked at $53.5M in Q4 2020. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Perceptive Advisors held 1,217,325 shares of Adaptive Biotechnologies worth $26.1M as of Q2 2026.
Perceptive Advisors bought 1,064,825 Adaptive Biotechnologies shares in Q2 2026, an estimated $16.3M.
Adaptive Biotechnologies made up 0.39% of Perceptive Advisors's portfolio in Q2 2026, its #51 holding.
Perceptive Advisors first reported a position in Adaptive Biotechnologies in Q2 2019 and has held it in 14 quarters since.
Perceptive Advisors's Adaptive Biotechnologies position peaked at $53.5M in Q4 2020.
300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.